IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide, which is characterized by the predominant deposition of IgA in the glomerular mesangium. Although prevalence of disease burden varies geographically, it substantially contributes to nearly half of the primary glomerular diseases and an increased risk of end stage renal disease (ESRD) in China [1]. Remarkably, ESRD occurs in approximately 40% of patients about 20 years after diagnosis [2].
